These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 16596481

  • 1. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP, McInnes C.
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [Abstract] [Full Text] [Related]

  • 2. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
    McInnes C, Wang S, Anderson S, O'Boyle J, Jackson W, Kontopidis G, Meades C, Mezna M, Thomas M, Wood G, Lane DP, Fischer PM.
    Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
    [Abstract] [Full Text] [Related]

  • 3. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M, Gortat A, Mondragón L, Bachs O, Pérez-Payá E.
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [Abstract] [Full Text] [Related]

  • 4. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
    Pratt DJ, Bentley J, Jewsbury P, Boyle FT, Endicott JA, Noble ME.
    J Med Chem; 2006 Sep 07; 49(18):5470-7. PubMed ID: 16942020
    [Abstract] [Full Text] [Related]

  • 5. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
    Kim MK, Min J, Choi BY, Lim H, Cho YH, Lee CH.
    J Microbiol Biotechnol; 2007 Oct 07; 17(10):1712-6. PubMed ID: 18156791
    [Abstract] [Full Text] [Related]

  • 6. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
    Vulpetti A, Casale E, Roletto F, Amici R, Villa M, Pevarello P.
    J Mol Graph Model; 2006 Mar 07; 24(5):341-8. PubMed ID: 16260160
    [Abstract] [Full Text] [Related]

  • 7. 4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4).
    Tsou HR, Otteng M, Tran T, Floyd MB, Reich M, Birnberg G, Kutterer K, Ayral-Kaloustian S, Ravi M, Nilakantan R, Grillo M, McGinnis JP, Rabindran SK.
    J Med Chem; 2008 Jun 26; 51(12):3507-25. PubMed ID: 18494457
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
    McIntyre NA, McInnes C, Griffiths G, Barnett AL, Kontopidis G, Slawin AM, Jackson W, Thomas M, Zheleva DI, Wang S, Blake DG, Westwood NJ, Fischer PM.
    J Med Chem; 2010 Mar 11; 53(5):2136-45. PubMed ID: 20146435
    [Abstract] [Full Text] [Related]

  • 9. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
    Dessalew N, Bharatam PV.
    Eur J Med Chem; 2007 Jul 11; 42(7):1014-27. PubMed ID: 17335939
    [Abstract] [Full Text] [Related]

  • 10. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2.
    Horiuchi T, Nagata M, Kitagawa M, Akahane K, Uoto K.
    Bioorg Med Chem; 2009 Dec 01; 17(23):7850-60. PubMed ID: 19889545
    [Abstract] [Full Text] [Related]

  • 11. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP, Paruch K, Alvarez C, Doll RJ, Keertikar K, Duca J, Fischmann TO, Hruza A, Madison V, Lees E, Parry D, Seghezzi W, Sgambellone N, Shanahan F, Wiswell D, Guzi TJ.
    Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6216-9. PubMed ID: 17904366
    [Abstract] [Full Text] [Related]

  • 12. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
    Elgazwy AS, Ismail NS, Elzahabi HS.
    Bioorg Med Chem; 2010 Nov 01; 18(21):7639-50. PubMed ID: 20851615
    [Abstract] [Full Text] [Related]

  • 13. Towards more accurate pharmacophore modeling: Multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2.
    Zou J, Xie HZ, Yang SY, Chen JJ, Ren JX, Wei YQ.
    J Mol Graph Model; 2008 Nov 01; 27(4):430-8. PubMed ID: 18786843
    [Abstract] [Full Text] [Related]

  • 14. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
    Richardson CM, Williamson DS, Parratt MJ, Borgognoni J, Cansfield AD, Dokurno P, Francis GL, Howes R, Moore JD, Murray JB, Robertson A, Surgenor AE, Torrance CJ.
    Bioorg Med Chem Lett; 2006 Mar 01; 16(5):1353-7. PubMed ID: 16325401
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
    Ibrahim DA, Ismail NS.
    Eur J Med Chem; 2011 Dec 01; 46(12):5825-32. PubMed ID: 22000924
    [Abstract] [Full Text] [Related]

  • 16. Structure-guided discovery of cyclin-dependent kinase inhibitors.
    Fischmann TO, Hruza A, Duca JS, Ramanathan L, Mayhood T, Windsor WT, Le HV, Guzi TJ, Dwyer MP, Paruch K, Doll RJ, Lees E, Parry D, Seghezzi W, Madison V.
    Biopolymers; 2008 May 01; 89(5):372-9. PubMed ID: 17937404
    [Abstract] [Full Text] [Related]

  • 17. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
    Kontopidis G, McInnes C, Pandalaneni SR, McNae I, Gibson D, Mezna M, Thomas M, Wood G, Wang S, Walkinshaw MD, Fischer PM.
    Chem Biol; 2006 Feb 01; 13(2):201-11. PubMed ID: 16492568
    [Abstract] [Full Text] [Related]

  • 18. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
    Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, Hajdúch M, Srovnal J, de Azevedo WF, Orság M, Paprskárová M, Rolcík J, Látr A, Fischer PM, Strnad M.
    J Med Chem; 2006 Nov 02; 49(22):6500-9. PubMed ID: 17064068
    [Abstract] [Full Text] [Related]

  • 19. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
    Cho YS, Borland M, Brain C, Chen CH, Cheng H, Chopra R, Chung K, Groarke J, He G, Hou Y, Kim S, Kovats S, Lu Y, O'Reilly M, Shen J, Smith T, Trakshel G, Vögtle M, Xu M, Xu M, Sung MJ.
    J Med Chem; 2010 Nov 25; 53(22):7938-57. PubMed ID: 21038853
    [Abstract] [Full Text] [Related]

  • 20. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK, Dessalew N, Bharatam PV.
    Eur J Med Chem; 2006 Nov 25; 41(11):1310-9. PubMed ID: 16890327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.